Acute DVT ‐ antiplatelet agents plus BMP vs BMP alone
- Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 500 participantsVery low
It is very uncertain whether acute DVT ‐ antiplatelet agents plus BMP changes post‐thrombotic syndrome compared with BMP alone (very low certainty).
It is very uncertain whether acute DVT ‐ antiplatelet agents plus BMP changes adverse events compared with BMP alone (very low certainty).
The review found no eligible studies for this question.
Chronic DVT ‐ antiplatelet agents plus BMP may leads to lower recurrent VTE ‐ early, intermediate and long term compared with BMP plus placebo (low certainty).
Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in major bleeding compared with BMP plus placebo (moderate certainty).
Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in pulmonary embolism (fatal/non‐fatal) compared with BMP plus placebo (moderate certainty).
Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in mortality ‐ intermediate and long term compared with BMP plus placebo (moderate certainty).
The review found no eligible studies for this question.
Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in adverse events compared with BMP plus placebo (moderate certainty).
It is very uncertain whether chronic DVT ‐ antiplatelet agents plus BMP changes recurrent VTE ‐ early and intermediate compared with BMP alone (very low certainty).